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Chikungunya virus (CHIKV), an emerging mosquito-
borne Alphavirus, causes debilitating rheumatic dis-
ease in humans that can last for weeks to months.
Starting in 2004, a CHIKV outbreak in the Indian
Ocean region affected millions of people, and infected
travelers introduced CHIKV to new regions. The
pathogenesis of CHIKV is poorly understood, and no
approved vaccines or specific therapies exist. A major
challenge to the study of CHIKV disease is the lack of
a small animal model that recapitulates the major
outcomes of human infection. In this study, the
pathogenesis of CHIKV in C57BL/6J mice was investi-
gated using biological and molecular clones of CHIKV
isolated from human serum (CHIKV SL15649). After
14-day-old mice were inoculated with CHIKV SL15649
in the footpad, they displayed reduced weight gain
and swelling of the inoculated limb. Histologic anal-
ysis of hind limb sections revealed severe necrotizing
myositis, mixed inflammatory cell arthritis, chronic
active tenosynovitis, and multifocal vasculitis. Inter-
estingly, these disease signs and viral RNA persisted
in musculoskeletal tissues for at least 3 weeks after
inoculation. This work demonstrates the develop-
ment of a mouse model of CHIKV infection with clin-
ical manifestations and histopathologic findings that
are consistent with the disease signs of CHIKV-in-
32fected humans, providing a useful tool for studying
viral and host factors that drive CHIKV pathogenesis
and for evaluating potential therapeutics against this
emerging viral disease. (Am J Pathol 2011, 178:32–40; DOI:
10.1016/j.ajpath.2010.11.018)
Chikungunya virus (CHIKV), O’nyong-nyong virus, Ma-
yaro virus, and Ross River virus are among a group of
mosquito-transmitted alphaviruses that cause debilitating
pain and inflammation of musculoskeletal tissue in hu-
mans.1–4 These viruses are an emerging threat because
of their ability to initiate explosive epidemics,3,5 including
a 1979–1980 epidemic of Ross River fever in the South
Pacific, which involved more than 60,000 patients,3 and a
1959–1962 epidemic of O’nyong-nyong fever in Africa,
which involved at least 2 million patients.6 In 2004, re-
emergence of CHIKV resulted in an epidemic that
caused millions of cases in multiple countries in the In-
dian Ocean region, including 270,000 cases on Reunion
Island and an estimated 1.4 million to 6.5 million cases in
India.7,8 The ability of these viruses to spread in a human
to mosquito to human transmission cycle in the absence
of animal reservoirs is particularly concerning because
this increases the likelihood of establishing epidemics in
new areas, including Europe and the Western Hemi-
sphere. This possibility was demonstrated by a CHIKV
outbreak in Italy in 2007 that resulted in more than 250
identified cases and included the detection of CHIKV in
local mosquito populations.9,10
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AJP January 2011, Vol. 178, No. 1The name chikungunya, from the Kimakonde language
of Tanzania, which translates as “that which bends up the
joints,” reflects the severe and debilitating rheumatic symp-
toms that are experienced by most individuals.11 Although a
small subset of people experience atypical outcomes,
which include potentially life-threatening multiorgan failure
and encephalitis, epidemiologic studies established unusu-
ally severe joint pain as the distinguishing and most com-
mon feature of CHIKV infection.12,13 In addition to joint pain,
recent studies have identified severe tenosynovitis and my-
ositis as prominent clinical features of infection.14–17 The
severe pain is chronic, typically lasting from weeks to
months. Up to 57% of patients report persistent rheumatic
symptoms 15 months after initial diagnosis.18
The study of the pathogenesis of CHIKV disease has
been hampered by the lack of a small animal model of
disease, although several recent studies in mice have
made progress. Neonatal mice and mice deficient in the
type I interferon receptor were found to be highly sus-
ceptible to CHIKV infection.19 Although CHIKV was de-
tected in muscle and joint tissue in these mice, the patho-
logical outcomes in these tissues were not addressed,19
and these models may be more relevant for studying the
pathogenesis of atypical CHIKV disease. Ziegler et al20
described severe skeletal muscle necrosis and inflam-
mation after CHIKV infection of outbred strains of mice.
These studies were promising; however, whether in-
fected mice developed other musculoskeletal conditions,
such as arthritis, was not reported. In addition to studies
in mice, CHIKV pathogenesis was recently investigated
in cynomolgus macaques.21 Infected macaques devel-
oped features consistent with human disease, such as
fever, rash, and swelling in wrist and ankle joints. How-
ever, musculoskeletal disease signs were only observed
in animals inoculated with very high doses of virus (107
PFU). Therefore, a critical need remains for a model sys-
tem that will allow detailed molecular and genetic analy-
ses of the major aspects of CHIKV-induced disease.
In this report, we describe the development of a new
small animal model in which infection of young C57BL/6J
mice with a clinical isolate of CHIKV (CHIKV SL15649) led to
gross swelling of the inoculated foot, induction of mixed
inflammatory cell arthritis in the feet and tarsi, and severe
tenosynovitis and myositis. Flow cytometric analyses of the
musculoskeletal infiltrates identified natural killer cells, neu-
trophils, monocytes/macrophages, and lymphocytes as
major cell infiltrates in musculoskeletal tissues. Similar to
human infection, disease signs persisted for at least 3
weeks after inoculation. A full-length molecular clone of
CHIKV SL15649 recapitulated the disease induced by the
natural isolate, thereby providing us with the tools to study




All studies with viable CHIKV were performed in certified
BSL-3 laboratories in biological safety cabinets usingbiosafety protocols that were approved by the Institu-
tional Biosafety Committees of the University of Colorado,
Denver, and the University of North Carolina at Chapel
Hill.
Isolation and Sequence Analysis of CHIKV
Serum samples were collected from febrile patients in Sri
Lanka during the 2006 CHIKV outbreak.22 Samples were
confirmed to be CHIKV positive by a CHIKV-specific PCR
assay. A total of 100 L of serum was inoculated onto
Vero cell (ATCC CCL-81) monolayers in 6-well dishes,
cells were observed for the development of a cytopathic
effect, and culture supernatants were collected at 72 hours
after inoculation. These supernatants were diluted onto new
Vero cell monolayers and overlayed with 0.5% immunodif-
fusion-grade agarose (MP Biomedical, Cleveland, OH);
then individual, well isolated plaques were collected.
Plaque-purified viruses were amplified 1 on Vero cells and
viral titers determined by plaque assay on Vero cells. TRIzol
reagent (Invitrogen, Carlsbad, CA) was added to an aliquot
of infected Vero cell supernatant, and CHIKV RNA was
purified using an RNA isolation kit (Invitrogen) according to
the manufacturer’s instructions. RNA was reverse tran-
scribed, and the CHIKV genome was amplified by PCR
using Platinum Pfx Polymerase (Invitrogen). The genome
was amplified in a series of 500-bp fragments overlapping
by 100 to 150 bp. Amplicons were cloned into pCR-Blunt
using the Zero Blunt PCR Cloning Kit (Invitrogen). The se-
quence of the 5= untranslated region was determined using
the 5= SMART RACE cDNA Amplification Kit according
to the manufacturer’s instructions (Clontech, Mountain
View, CA). Forward and reverse sequencing of two inde-
pendent amplicons per region was performed, and the
complete genomic sequence was assembled (GenBank:
GU189061.1).
Construction of CHIKV Strain SL15649 cDNA
Clone and Generation of Infectious Virus
Genomic cDNA fragments based on the SL15649 genome
sequence (GenBank: GU189061.1) were commercially
synthesized (BioBasic, Markham, ON, Canada) to create
three constructs, each spanning approximately one-third of
the CHIKV genome. The three fragments were assembled
into the full-length genome using unique AgeI and XhoI sites
and inserted into pUC57 to create the infectious clone
(icCHIKVSL15649). The icCHIKVSL15649 plasmid was lin-
earized using NotI and transcribed in vitro using an mMes-
sage mMachine SP6 transcription kit (Ambion, Austin, TX)
to yield 5=-capped genomic RNA. Viral RNA was electropo-
rated into BHK-21 cells. Culture supernatants were col-
lected at 24 hours after electroporation, centrifuged to re-
move cellular debris, aliquoted, and stored at 80°C until
virus titers were quantified by plaque assay.
Mouse Experiments
C57BL6/J mice were obtained from the Jackson Labora-
tory and bred in-house. Fourteen-day-old mice were in-
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diluent (PBS1% bovine calf serum) in a 10-L volume.
Control animals were inoculated with diluent alone. Mice
were housed with the mother until they were 21 days old.
Mice were monitored for disease signs and weighed at
24-hour intervals, and no mortality was observed in the
CHIKV-infected mice. Calipers were used to perform dor-
soventral measurements of the feet and mediolateral
measurements of the tarsi. Animal husbandry and exper-
iments were performed in accordance with all University
of Colorado, Denver, and University of North Carolina at
Chapel Hill Institutional Animal Care and Use Committee
guidelines.
Virus Tissue Titers
At the times indicated, mice were sacrificed and per-
fused by intracardial injection with 1 PBS. Tissues were
dissected, weighed, and homogenized, and the amount
of infectious CHIKV present was determined by plaque
assay on Vero cells.
Histologic Analysis
At the times indicated, mice were sacrificed and per-
fused by intracardial injection with 4% paraformalde-
hyde, pH 7.3. Hind limb tissues, not including the femur,
were embedded in paraffin and 5-m sections were pre-
pared. To determine the extent of inflammation and tissue
disease, tissues were stained with H&E. Sections were
evaluated for bone marrow hyperplasia, necrosis, inflam-
mation, regeneration, mineralization, fibrosis, edema, vas-
culitis, tenosynovitis, synovitis, and tendonitis. Severity
grades were assigned based on the following scale: 1,
minimal; 2, mild; 3, moderate; 4, marked; asterisk, present;
and minus sign, absent.
Flow Cytometry
Mice were inoculated as described; sacrificed by exsan-
guination at 3, 5, and 7 days after inoculation; and perfused
with 1 PBS. Hind limb skin was removed, and hind limbs
below the knee were dissected and incubated for 45 min-
utes at 37°C in digestion buffer [RPMI, 10% fetal bovine
serum, 15 mmol/L HEPES, 2.5 mg/ml of collagenase A
(Roche, Basil, Switzerland), and 1.7 mg/ml of DNase I
(Sigma, St. Louis, MO)]. Digested tissues were passed
through a 40-m cell strainer, pelleted, washed, and resus-
pended in RPMI medium. Total viable cells were quantified
by counting trypan blue–stained cells. Isolated cells were
incubated with antimouse FcRII/III (2.4G2; BD Pharmin-
gen, San Diego, CA) for 20 minutes on ice and then
stained in fluorescence-activated cell sorter staining
buffer (1 Hanks balanced salt solution, 1% fetal bovine
serum) with the following antibodies: anti-CD45-Biotin,
anti-CD11c-phycoerythrin-Texas Red, anti-NK1.1-phyco-
erythrin, anti-CD3-fluorescein isothiocyanate, anti-CD4-
Pacific Blue, anti-CD8-Pacific Orange, anti-F4/80-fluores-
cein isothiocyanate, CD115-fluorescein isothiocyanate,
anti-CD11b-phycoerythrin-Cy7, anti–major histocompati-
bility complex class II-allophycocyanin, or anti-GR-1-phy-coerythrin (all from eBioscience, San Diego, CA). Biotin
conjugates were detected with Streptavidin-Peridinin
Chlorophyll Protein Complex (eBioscience). Cells were
fixed overnight in 2% paraformaldehyde and analyzed on
a cyan cytometer (Becton Dickinson, Franklin Lakes, NJ)
using Summit software.
RT-PCR
At 2, 14, and 21 days after inoculation, uninfected or
CHIKV-infected mice (three mice per group) were sacri-
ficed and perfused by intracardial injection with 1 PBS.
Tissues were homogenized in 1 ml of TRIzol (Invitrogen),
and total RNA was isolated using the PureLink RNA Kit
(Invitrogen). RNA was reverse transcribed with super-
script III (Invitrogen) and analyzed by 25 cycles of PCR
for the presence of -actin or 30 cycles of PCR for the
presence of CHIKV using previously published primers
specific for the E1 region of the genome.23 The ic-
CHIKVSL15649 plasmid was used as a positive control.
RNA samples that had not been subjected to reverse
transcription were used as a negative control.
Results
To investigate the capacity of a CHIKV clinical isolate to
cause disease in a mouse model, 14-day-old C57BL/6J
mice were inoculated with 100 PFU of CHIKV SL15649,
which was isolated from a febrile CHIKV-positive Sri Lan-
kan patient as described in the “Materials and Methods”
section. In addition to the virus that was directly amplified
from the human serum, mice were also inoculated with
three different plaque-purified CHIKV SL15649 isolates
(PL1, PL2, and PL3) or virus inactivated by UV light.
Control mice were inoculated with virus diluent alone.
Compared with control mice or mice inoculated with UV-
treated virus, inoculation with CHIKV SL15649 or any of
the three plaque-purified isolates resulted in diminished
weight gain (Figure 1, A–C). Strikingly, as evidenced by
both caliper measurements and histologic analysis, all
mice inoculated with live virus developed intense gross
swelling and edema of the left foot (Figure 1, D and E)
and tarsus (data not shown). Swelling began 2 days after
inoculation (data not shown) and persisted at least 1
week (Figure 1, D and E). Analysis of the noninoculated
foot demonstrated that inflammatory infiltrates were
present at 7 days after inoculation (Figure 1E). However,
these infiltrates appeared less extensive than those ob-
served in the inoculated foot, and no gross or histopatho-
logic evidence of swelling or edema was observed in
footpad tissues contralateral to the site of inoculation. To
investigate whether tissue swelling and the magnitude of
inflammation correlated with differences in the amount of
virus present in musculoskeletal tissues ipsilateral or con-
tralateral relative to the site of inoculation, the amounts of
infectious virus present in tarsus or foot tissue of mice
inoculated with plaque-purified CHIKV SL15649 was
quantified by plaque assay at 1 and 4 days after inocu-
lation (Figure 1F). Approximately 100-fold more virus was
present in left tarsus or foot tissue compared with the
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inoculation, suggesting that CHIKV SL15649 spreads to
distal sites, but the peak viral titers at sites distal to the
site of inoculation are diminished. These results suggest
that the SL15649 virus, which is not mouse adapted,
does not spread efficiently from the inoculated foot. It
remains to be determined whether the lack of swelling in
the noninoculated foot is due to this difference in viral
replication or some other mechanism.
Debilitating rheumatic disease signs and symptoms,
such as severe joint pain and tenosynovitis, are prom-
inent features of CHIKV infection of humans.14 –16
Therefore, we next investigated whether inoculation of
mice with CHIKV SL15649 resulted in musculoskeletal
tissue disease consistent with the disease signs of
CHIKV-infected humans. For these experiments, 14-day-
old C57BL/6J mice were inoculated with diluent alone
(control) or 100 PFU of plaque-purified CHIKV SL15649 in
the footpad, which resulted in 100% morbidity and 0%
mortality. At 1, 3, 7, 10, 14, and 21 days after inoculation,
mice were sacrificed, perfused by intracardial injectionwith 4% paraformaldehyde, and H&E-stained tissue sec-
tions generated from the left and right hind limbs were
evaluated for disease. The major pathological findings
from these studies are given in Figure 2 and Table 1. In
contrast to control-inoculated mice (Figure 2A), by 7 days
after inoculation mice inoculated with CHIKV SL15649
had developed a mixed inflammatory cell arthritis con-
taining histiocytes, neutrophils, lymphocytes, and rare
plasma cells in various joints of the feet (Figure 2B) and
the tarsi (data not shown). Virus-infected mice displayed
severe chronic active tenosynovitis (Figures 2, C and D)
with coagulative necrosis that did not involve the blood
vessels, and this was not observed in control-inoculated
mice. Furthermore, in contrast to skeletal muscle tissue of
control mice (Figure 2, E and G), necrotizing myositis was
observed in skeletal muscle tissues of CHIKV SL15649–
inoculated mice, such as the gastrocnemius muscle (Fig-
ures 2, F and H) and quadriceps femoris muscle (data
not shown). In addition to the major pathological findings
of arthritis, tenosynovitis, and myositis, CHIKV SL15649–
Figure 1. Chikungunya virus (CHIKV)–induced
disease signs. Fourteen-day-old C57BL/6J mice
were inoculated with virus diluent only (control),
100 PFU of CHIKV SL15649, 100 PFU of UV light–
inactivated CHIKV SL15649, or 100 PFU of three
independent plaque-purified isolates of CHIKV
SL15649 (PL1, PL2, PL3). Mice were weighed at
24-hour intervals, and percentage of starting body
weight (A), actual body weights (B), and the aver-
age rate of weight gain in grams per day (C) were
determined (n  three mice per group). D: Four-
teen-day-old C57BL/6J mice were inoculated with
virus diluent only (control) or 100 PFU of plaque-
purified CHIKV SL15649. At 7 days after inocula-
tion, a dorsoventral measurement of the left foot
was performed (n  four mice per group). ***P 
0.001 as determined by 2-tailed t-test. E: Fourteen-
day-old C57BL/6J mice were inoculated with virus
diluent only (control) or 100 PFU of plaque-puri-
fied CHIKV SL15649. At 7 days after inoculation,
mice were sacrificed and perfused by intracardial
injection with 4% paraformaldehyde. Tissue sec-
tions were stained with H&E, and the footpads
were assessed for evidence of inflammation and
edema (asterisk). Images are representative of at
least three mice per group. F: Fourteen-day-old
C57BL/6J mice were inoculated with 100 PFU of
plaque-purified CHIKV SL15649. At 1 day after in-
oculation (n  4) and 4 days after inoculation (n 
4), mice were sacrificed and perfused by intracar-
dial injection with 1 PBS. Left tarsus or foot (filled
circles) and right tarsus or foot (open circles) were
dissected, weighed, and homogenized, and the
amount of infectious virus present was quantified
by plaque assays. Dashed line indicates the limit of
detection. ***P  0.0001 as determined by two-
tailed t-tests.inoculated mice displayed multifocal vasculitis (Figure 2,
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marrow compared with control-inoculated mice (Figures
2, K and L). Although viral loads at 1 and 4 days after
inoculation were significantly higher in tissues in the left
hind limb (site of inoculation), similar types of inflamma-
tory lesions were present in right hind limb tissues (Table
1). The lesions in the right hind limb tended to be milder
in severity at 3 and 7 days after inoculation and similar in
severity at 10 and 14 days after inoculation (Table 1).
Although many healthy adults recover from CHIKV infec-
tion within days or weeks after the onset of disease signs,
a number of studies indicate that a large fraction (up to
57%) of CHIKV-infected humans have persistent arthral-
gia for months to years.18,24–28 Importantly, ongoing
signs of inflammation were observed in joint tissues ofCHIKV SL15649–inoculated mice at 21 days after inoc-
ulation, whereas both a fibrous response and regenera-
tive response were evident in skeletal muscle tissue (Ta-
ble 1). Taken together, these findings indicate that
inoculation of 14-day-old C57BL/6J mice with CHIKV
strain SL15649 results in acute histopathologic inflamma-
tory changes of musculoskeletal tissues, including joints,
tendons, and skeletal muscle, which is consistent with the
disease signs of CHIKV-infected humans.29 To further
characterize the inflammatory response in musculoskel-
etal tissues, infiltrating leukocytes were isolated from hind
limbs at 3, 5, and 7 days after inoculation and quantified
by flow cytometry as described in the “Material and Meth-
ods” section. At early times after inoculation (3 and 5
Figure 2. Chikungunya virus (CHIKV) SL15649-
induced musculoskeletal disease. Fourteen-day-
old C57BL/6J mice were inoculated with virus dil-
uent only (control) or 100 PFU of plaque-purified
CHIKV SL15649. At 7 days after inoculation, mice
were sacrificed and perfused by intracardial injec-
tion with 4% paraformaldehyde. Tissue sections
were stained with H&E and evaluated for tissue
disease. Metatarsophalangeal joint of control-inoc-
ulated (A) or CHIKV-inoculated (B) inoculated
mouse. Asterisks indicate bone. Pelvic limb ten-
don of control-inoculated (C) or CHIKV-inocu-
lated (D) mouse. Arrows indicate tendon sheath.
Gastrocnemius muscle of control-inoculated (E
and G) or CHIKV-inoculated (F and H) mouse.
Pelvic limb vasculitis of CHIKV-inoculated mouse
(I and J). Asterisk indicates normal vessel (I).
Arrowheads indicate vessels with vasculitis (I).
Pelvic limb bone marrow of control-inoculated (K)
or CHIKV-inoculated (L) mouse. Images are rep-
resentative of at least three mice per group (M). At
3 (n  3), 5 (n  3), and 7 (n  3) days after
inoculation, leukocytes were isolated from hind
limb tissues of control-inoculated and CHIKV
SL15649–inoculated mice. Isolated cells were
counted and analyzed by flow cytometry as de-
scribed in the “Materials and Methods” section. Total
numbers of natural killer cells (NK1.1/CD3),
monocytes/macrophages (F4/80/CD11b), CD4 T
lymphocytes (CD3/CD8/CD4), and CD8 T lym-
phocytes (CD3/CD8/CD4) isolated from the left
and right hind limbs are shown. Each bar represents
the arithmetic mean  SEM of three mice per group.days after inoculation), natural killer (CD3/NK1.1) cells
regener
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were the predominant cell types detected in musculo-
skeletal tissues of the left hind limb. In contrast, by this
method there was no detectable increase above back-
ground numbers of leukocytes in musculoskeletal tissues
of the right hind limb (Figure 2M, first panel). This finding
is consistent with the histologic results, where tissues in
the noninoculated limb exhibited inflammatory cell infil-
trates, but these were reduced compared with the inoc-
ulated limb. By 7 days after inoculation, the inflammatory
lesions in the inoculated foot were characterized by the
presence of natural killer cells, monocytes/macrophages
(F4/80/CD11b), and both CD4 and CD8 T lympho-
cytes (CD3/CD4/CD8 and CD3/CD4/CD8, re-
spectively) (Figure 2M). In addition, analyses with addi-
tional cell surface markers suggested the presence of a
heterogenous mix of myeloid cell phenotypes and other
cell types (data not shown); however, future studies are
required to fully characterize the complexities of the in-
flammatory response to CHIKV infection.
The data described thus far indicate that inoculation of
C57BL/6J mice with CHIKV SL15649 provides a robust
animal model of CHIKV-induced musculoskeletal tissue
disease to investigate mechanisms of pathogenesis. To
establish a viral reverse genetics system for this model
and confirm that the inflammatory condition associated
with CHIKV SL15649 was due to CHIKV and not an un-
identified contaminant within the virus preparation,
CHIKV SL15649 genomic cDNA fragments were com-
mercially synthesized and assembled into a full-length
cDNA (icCHIKV SL15649) as described in the “Materials
and Methods” section. Comparative analysis of multistep
replication kinetics of icCHIKV SL15649 and CHIKV
SL15649 in both Vero cells and C6/36 mosquito cells
indicated that in vitro replication characteristics of the
molecularly and biologically cloned viruses were indistin-
guishable (data not shown). To assess the in vivo viru-
lence of the molecular clone–derived virus, C57BL/6J
mice were inoculated with either the natural isolate







Control R — — — —
Control L — — — —
Control L — — — —
1 R — — — —
1 L — — — —
3 R 2 — 1 —
3 L 2 — 2 —
7 R 4 2 2 —
7 L 4 4 4 4
10 R 3 2 3 4
10 L 3 2 2 2
14 R 2 2 3 2
14 L 2 2 3 4
21 R 2 1 2 2
21 L 2 1 2 4
E, edema; F, fibrosis; I, inflammation; M, mineralization; N, necrosis; R,
*, present; 1, minimal; 2, mild; 3, moderate; 4, marked.SL15649 virus or the clone-derived icCHIKV SL15649virus, and the mice were evaluated for virus-induced
disease signs and inflammatory musculoskeletal tissue
disease. Similar to CHIKV SL15649 (Figure 1B), inocula-
tion of icCHIKV SL15649 induced intense swelling of the
left foot and tarsus (Figure 3D). In addition, the distribu-
tion and degree of inflammation within musculoskeletal
tissues, including the tarsi (Figure 3, A–C), various joints
of the feet (data not shown), and hind limb skeletal mus-
cle tissue (data not shown), were similar in mice inocu-
lated with either CHIKV SL15649 or icCHIKV SL15649. To
assess whether icCHIKV SL15649 replicated in tarsus or
foot tissues similar to CHIKV SL15649, the amounts of
infectious virus was quantified by plaque assay at 1, 4,
and 7 days after inoculation (Figure 3E). Similar to CHIKV
SL15649 (Figure 1D), significantly more virus was
present in left tarsus or foot tissue compared with the
right tarsus or foot tissue at all times evaluated. Notably,
despite the presence of inflammatory histopathologic
changes, the amount of infectious virus present in right
tarsus or foot tissue was below the limit of detection by 7
days after inoculation. To determine whether the his-
topathologic changes observed at late times after inoc-
ulation (14 and 21 days after inoculation; Table 1) were
associated with the persistence of CHIKV, we isolated
total RNA at 2, 14, and 21 days after inoculation from the
left ankle, right ankle, left quadriceps, right quadriceps,
and the spleen and performed RT-PCR analyses. As ex-
pected, CHIKV RNA was readily detected in all tissues at
2 days after inoculation (Figure 3F). Interestingly, CHIKV
RNA was detected in the left and right ankles at 14 and
21 days after inoculation but not the other tissues (Figure
3F). No CHIKV-specific RT-PCR signal was detected in
RNA samples isolated from tissues of mock-inoculated
control mice or in the absence of reverse transcription
(Figure 3F). These findings indicate that though CHIKV is
readily cleared from most tissues after the acute stage of
infection, CHIKV RNA persists in joint tissues for at least
3 weeks after inoculation, and the persistence of viral
RNA is associated with ongoing inflammation within joint-
Metatarsal muscle
V TS S TI R M F E
— — — — — — — — —
— — — — — — — — —
— — — — — — — — —
1 — — — — — — — —
2 — — — 3 — 2 1 2
1 — — — — —
3 — — — 3 * 2 2 3
4 1 — — 1 * 1 2 3
4 1 4 — 4 * 4 4 4
4 2 4 — 3 * 4 3 4
3 2 — — 1 * 3 2 2
3 3 — 1 1 — 2 2 2
3 — 3 3 1 * 4 3 3
2 4 — 2 — * 2 2 1
3 — 3 4 2 * 4 2 3
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These results demonstrate that infection of young mice
with a clinical CHIKV isolate results in a spectrum of
histopathologic changes, including mixed inflammatory
cell arthritis, tenosynovitis, and myositis, that is similar to
the distinguishing features of classic CHIKV-induced dis-
Figure 3. A cDNA clone of chikungunya virus (CHIKV) SL15649 induces
inflammation of the musculoskeletal tissues. Fourteen-day-old C57BL/6J
mice were inoculated with virus diluent only (control), 100 PFU of plaque-
purified CHIKV SL15649, or 100 PFU of cDNA clone–derived CHIKV SL15649
(icCHIKV SL15649). At 10 days after inoculation, mice were sacrificed and
perfused by intracardial injection with 4% paraformaldehyde. Tissue sections
from control-inoculated (A), CHIKV SL15649–inoculated (B), and icCHIKV
SL15649–inoculated mice (C) were stained with H&E and evaluated for tissue
disease. Shown are images of the left tarsus. Asterisks indicate bone. Images
are representative of at least three mice per group. D: Fourteen-day-old
C57BL/6J mice were inoculated with virus diluent only (control) or 100 PFU
of icCHIKV SL15649. At 7 days after inoculation, dorsoventral measurements
of the left and the right foot were performed (n  four mice per group). Data
are representative of at least two independent experiments. ***P  0.0001 as
determined by two-tailed t-test. E: Fourteen-day-old C57BL/6J mice were
inoculated with 100 PFU of icCHIKV SL15649. At 1 (n  4), 4 (n  4), and
7 (n  4) days after inoculation, mice were sacrificed and perfused by
intracardial injection with 1 PBS. Left tarsus or foot (filled circles) and right
tarsus or foot (open circles) were dissected, weighed, and homogenized, and
the amount of infectious virus present was quantified by plaque assays.
Dashed line indicates the limit of detection. *P  0.0006 as determined by
two-tailed t-test. **P  0.002 as determined by two-tailed t-test. F: Fourteen-
day-old C57BL/6J mice were mock inoculated or inoculated with 100 PFU of
icCHIKV SL15649. At 2 (n  3), 14 (n  3), and 21 (n  3) days after
inoculation, mice were sacrificed and perfused by intracardial injection with
1 PBS. Left tarsus/foot (LA), right tarsus/foot (RA), left quadriceps femoris
(LQ), right quadriceps femoris (RQ), and spleens (S) were homogenized in
TRIzol. Isolated RNA was analyzed for the presence of CHIKV RNA by
RT-PCR. Gel images are representative of three mice per group.ease in humans. A similar mouse model for the relatedarthritic alphavirus, Ross River virus, has led to the iden-
tification of several host pathways, including the host
complement cascade, as key drivers of virus-induced
arthritis and myositis,30–32 and this newly developed
mouse model will allow analysis of host pathways that
contribute to the pathogenesis of CHIKV-induced dis-
ease. Furthermore, reproduction of the disease caused
by the clinical isolate by the full-length infectious clone-
derived virus not only demonstrates a direct role for
CHIKV in driving the inflammatory pathological changes
but also allows for the use of this molecular clone to
identify viral determinants that regulate viral virulence
and virus-induced disease.
Recently, evidence of arthritis, tenosynovitis, and
myositis after inoculation of adult C57BL/6 mice with a
Reunion Island CHIKV isolate (LR2006-OPY1) or a pre-
sumably mouse-adapted Asian CHIKV isolate was re-
ported.33 Similar to our findings, Gardner et al33 ob-
served that CHIKV-induced swelling was restricted to the
inoculated foot, suggesting that neither the SL15649 virus
used in our studies nor the LR2006-OPY1 virus used by
Gardner et al disseminated efficiently in the mouse. In-
terestingly, some of the findings from Gardner et al dif-
fered from our findings. Whereas we observed clear ev-
idence of severe tendonitis (Figure 2D and Table 1),
Gardner et al reported that hind limb tendons appeared
unaffected. Furthermore, Gardner et al did not report any
evidence for CHIKV persistence in their model, although
this has been reported both in CHIKV-infected humans
and nonhuman primates.21,34 In contrast, we observed
ongoing inflammation in joint tissues at least 3 weeks
after inoculation, as well as joint-specific persistence of
CHIKV RNA. These differences may reflect the differ-
ences in mouse age or the virus isolate used in the two
studies and require further investigation.
A current limitation of our model is the unequal repli-
cation of the virus in tissues near and distal to the site of
inoculation, which is likely due to inefficient viral dissem-
ination. However, our generation of a molecular clone of
CHIKV SL15649, which exhibits the same phenotype,
combined with the availability of genetically engineered
mice provides the opportunity to investigate both the host
factors and virus genetic determinants that regulate
CHIKV dissemination and spread. Our analysis has
focused on the early acute stages of CHIKV-induced
inflammation; however, a subset of CHIKV-infected hu-
mans exhibit long-term joint pain,18 and it will be impor-
tant to assess the long-term consequences of CHIKV
infection in this model to determine whether it will repro-
duce the chronic aspects of the human disease and
thereby allow analysis of mechanisms underlying chronic
infection. As previously noted, our study demonstrated
that severe histopathologic changes persisted in muscu-
loskeletal tissues of CHIKV-infected mice for at least 3
weeks after inoculation (Table 1). Furthermore, although
CHIKV RNA was cleared from other peripheral tissues,
viral RNA was readily detected in ankle tissue at 3 weeks
after tinoculation, suggesting that the persistence of viral
RNA may drive chronic inflammatory responses. It will be
important to evaluate the mechanisms leading to CHIKV
persistence, including determination of whether the per-
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AJP January 2011, Vol. 178, No. 1sistence of viral RNA reflects ongoing viral replication or
the maintenance of some type of defective viral genome
within the joints. It is possible that viral persistence is due
to active evasion of host innate or adaptive immune re-
sponses by the virus. Interestingly, we and others have
recently demonstrated that several alphaviruses, includ-
ing CHIKV, actively antagonize STAT activation by both
type I and type II interferon, and it will be important to
assess whether evasion of the interferon response plays
any role in promoting persistence of CHIKV RNA within
the joints.35–37
Finally, there is a critical need to develop new thera-
pies for CHIKV-induced disease because there are cur-
rently no specific therapies to treat Alphavirus-induced
rheumatic disease. Treatment options are limited primar-
ily to nonsteroidal anti-inflammatory drugs, which provide
relief for a subset of patients.38 Therefore, in addition to
allowing for an in-depth analysis of the viral and host
factors that drive CHIKV-induced inflammatory disease,
this model should prove useful for testing potential ther-
apeutics for preventing or ameliorating the effects of
CHIKV-induced rheumatic disease.
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